Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab and Rituximab

BACKGROUND: CLL patients are usually only treated for progressive disease. However, the discovery of biological predictors of high risk of disease progression together with the development of newer more targeted therapies could change this paradigm. In this phase 2 study we tested the safety and eff...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Zent, Clive S., Call, Timothy G., Shanafelt, Tait D., Tschumper, Renee T., Jelinek, Diane F., Bowen, Deborah A., Secreto, Charla R., LaPlant, Betsy R., Kabat, Brian F., Kay, Neil E.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2008
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849723/
https://ncbi.nlm.nih.gov/pubmed/18759253
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.23824
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk